Personalis, Inc. PSNL
Regular-session close
After hours · Nov 20, 4:26 PM ET
- YTD
- +79.27%
- 1 year
- +72.34%
5D -1.00 (-6.31%)
- Market cap
- 1.55B
- Revenue (ttm)
- 80.77M
- Profit margin
- -147.74%
- EPS (ttm)
- -1.16
- Shares out
- 108.40M
- Forward P/E
- -14.53
- YTD return
- +79.27%
- 1-year return
- +72.34%
- 50-day average
- 15.93
- 200-day average
- 11.69
- Volume
- 3.34M
- Avg volume
- 2.56M
- Open
- 14.55
- Previous close
- 14.72
- Day's range
- 14.23 – 14.67
- 52-week range
- 4.96 – 18.89
- Beta
- 2.36
- Analysts
- Hold
- Price target
- 15.17 (+6.3%)
- Earnings date
- Feb 25, 2027
Key statistics
- Enterprise value
- 1.44B
- Price / sales
- 19.15
- Price / book
- 7.27
- Revenue growth
- 76.60%
- Free cash flow
- -59.35M
- Total cash
- 190.60M
- Total debt
- 37.20M
- Return on equity
- -62.14%
- Short % of float
- 9.64%
Fundamental scorecard
4 of 25 checks passed on PSNL’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: hold
- Target (low)
- 13.00
- Target (mean)
- 15.17
- Target (high)
- 16.25
- Strong buy0
- Buy1
- Hold4
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate -0.2325.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | -0.2365 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.26333 | -0.32 | -0.06 | -21.52% |
| Aug 4, 2026 | Jun 30, 2026 | -0.26333 | -0.30 | -0.04 | -13.93% |
| May 7, 2026 | Mar 31, 2026 | -0.23 | -0.29 | -0.06 | -26.09% |
| Feb 26, 2026 | Dec 31, 2025 | -0.31 | -0.26 | +0.05 | +16.13% |
| Nov 4, 2025 | Sep 30, 2025 | -0.28 | -0.24 | +0.04 | +14.29% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 6, 2026 | BTIG | down | Buy | Neutral |
| Jul 20, 2026 | Lake Street | down | Buy | Hold |
| Jul 20, 2026 | BTIG | main | Buy | Buy |
| Jul 20, 2026 | Needham | down | Buy | Hold |
| Jul 17, 2026 | Needham | main | Buy | Buy |
| Jul 9, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
About Personalis, Inc.
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- personalis.com
News
PSNL Merger Investigation: Personalis Investigated Over $16.25 per Share Take-Private Merger – Contact BFA Law if You Hold Shares
Are WAFD, PSNL, DAN, BWIN Obtaining Fair Deals for their Shareholders?
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL Personalis Q3 EPS $(0.32) Misses $(0.25) Estimate, Sales $25.596M Beat $21.850M Estimate
Tempus AI Earnings Ahead: Is TEM Set Up To Pop or Drop?
Your note
Sign in to keep a note on PSNL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BLOOM OLIVIA KYUSUK | Director | Stock Award(Grant) | May 11, 2026 | 27,265 |
| BOWMAN ARTHUR BLAINE | Director | Stock Award(Grant) | May 11, 2026 | 19,756 |
| CHEN RICHARD | President | Sale | Sep 17, 2026 | 169,882 |
| EASTHAM KARIN | Director | Stock Award(Grant) | May 11, 2026 | 19,756 |
| HALL CHRISTOPHER M. | Chief Executive Officer | Sale | Nov 2, 2026 | 199,415 |
| MOORE STEPHEN MICHAEL | Officer | Sale | Sep 17, 2026 | 90,257 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Merck & Co., Inc. | 12.96% | 14,044,943 | 200.42M | Sep 29, 2026 |
| ARK Investment Management, LLC | 6.57% | 7,119,390 | 101.59M | Sep 29, 2026 |
| Blackrock Inc. | 6.40% | 6,934,017 | 98.95M | Sep 29, 2026 |
| Lightspeed Management Company, L.L.C. | 5.63% | 6,101,850 | 87.07M | Sep 29, 2026 |
| Balyasny Asset Management LP | 4.57% | 4,958,942 | 70.76M | Sep 29, 2026 |
| Aberdeen Group plc | 3.21% | 3,480,949 | 49.67M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| abrdn Healthcare Investors | 2.03% | 2,204,516 | 31.46M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.98% | 2,142,395 | 30.57M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.73% | 1,878,903 | 26.81M | Sep 29, 2026 |
| abrdn Life Sciences Investors | 1.42% | 1,542,774 | 22.02M | Jun 29, 2026 |
| Columbia Acorn Trust-Columbia Acorn Fund | 1.18% | 1,277,628 | 18.23M | Jun 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 1.07% | 1,160,163 | 16.56M | Oct 30, 2026 |
